EGFR and colorectal cancer: Recently, in the pooled analysis of six RCTs (FIRE-3 trial, CALGB/SWOG 80405, PEAK, CRYSTAL, PRIME, 20050181) for RAS wild-type unresectable colorectal cancer, a correlation between the tumor location (right side or left side) and the therapeutic effect of molecular targeted drugs (BEV or anti-EGFR antibody) was reported [220].